Tapentadol Urine Screen with Reflex to Quantitation
Ordering Recommendation
Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out tapentadol exposure. For follow-up testing of a presumptive result, Tapentadol, Urine, Quantitative (2003128) is preferred.
New York DOH Approval Status
Specimen Required
Random urine.
Transfer 4 mL urine with no additives or preservatives to an ARUP Standard Transport Tube. (Min: 2 mL)
Room temperature.
Breast milk. Pharmaceutical preparation. Specimens exposed to repeated freeze/thaw cycles.
Ambient: 1 week: Refrigerated: 1 month; Frozen: 1 month
Methodology
Qualitative Enzyme Immunoassay/Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun-Sat
Reported
1-4 days
Reference Interval
Screen cutoff concentration: 200 ng/mL
Interpretive Data
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies. Specimens for which drugs or drug classes are detected by the screen are reflexed to a second, more specific technology (GC/MS and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
For medical purposes only; not valid for forensic use.
Modified FDA
Note
If the specimen screens positive, then Confirmation/Quantitation by LC-MS/MS (ARUP test code 2003128) will be added to confirm result. Additional charges apply.
Hotline History
CPT Codes
80307; if reflexed, add 80372 (Reflexed Alt Code: G0480 )
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
2012212 | Screen, Urine Interpretation | 54247-2 |
2012295 | Tapentadol, Urn, Screen | 72485-6 |
Aliases
- Nucynta
- Tapentadol, Qualitative